Amneal Pharmaceuticals (AMRX) Competitors $8.33 -0.06 (-0.72%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$8.24 -0.09 (-1.02%) As of 07/11/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRX vs. BBIO, BPMC, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and NUVLShould you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Amneal Pharmaceuticals vs. Its Competitors BridgeBio Pharma Blueprint Medicines Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent BridgeBio Pharma (NASDAQ:BBIO) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends. Which has more risk and volatility, BBIO or AMRX? BridgeBio Pharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Do insiders and institutionals believe in BBIO or AMRX? 99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, BBIO or AMRX? Amneal Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$221.90M39.76-$535.76M-$3.53-13.16Amneal Pharmaceuticals$2.79B0.93-$116.89M-$0.04-208.25 Do analysts rate BBIO or AMRX? BridgeBio Pharma presently has a consensus price target of $60.21, indicating a potential upside of 29.58%. Amneal Pharmaceuticals has a consensus price target of $11.60, indicating a potential upside of 39.26%. Given Amneal Pharmaceuticals' higher probable upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 3.00Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BBIO or AMRX more profitable? Amneal Pharmaceuticals has a net margin of -0.46% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-524.25% N/A -94.43% Amneal Pharmaceuticals -0.46%-188.26%5.34% Does the media refer more to BBIO or AMRX? In the previous week, BridgeBio Pharma had 12 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 15 mentions for BridgeBio Pharma and 3 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.71 beat BridgeBio Pharma's score of 0.46 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAmneal Pharmaceuticals beats BridgeBio Pharma on 8 of the 15 factors compared between the two stocks. Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRX vs. The Competition Export to ExcelMetricAmneal PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.63B$2.74B$5.62B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio-208.209.4228.1320.27Price / Sales0.93714.13428.6398.72Price / Cash6.04165.3637.4658.16Price / Book-23.804.608.045.49Net Income-$116.89M$31.26M$3.18B$250.45M7 Day Performance-2.69%4.80%3.62%4.78%1 Month Performance4.65%5.42%4.05%7.67%1 Year Performance15.86%-4.36%30.00%16.43% Amneal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRXAmneal Pharmaceuticals2.8174 of 5 stars$8.33-0.7%$11.60+39.3%+14.9%$2.63B$2.79B-208.208,100BBIOBridgeBio Pharma4.5848 of 5 stars$43.50-1.1%$58.85+35.3%+72.8%$8.35B$221.90M-12.32400Analyst UpgradeBPMCBlueprint Medicines1.2248 of 5 stars$128.40+0.0%$128.06-0.3%+9.8%$8.29B$508.82M-51.98640Positive NewsInsider TradeVRNAVerona Pharma PLC American Depositary Share2.3736 of 5 stars$91.20-0.4%$107.36+17.7%+394.0%$7.79B$42.28M-45.6030Trending NewsAnalyst ForecastROIVRoivant Sciences2.8364 of 5 stars$10.74-2.3%$17.50+62.9%+1.1%$7.47B$29.05M-42.96860Analyst UpgradeELANElanco Animal Health1.5088 of 5 stars$14.48-1.1%$15.33+5.9%+9.0%$7.27B$4.44B19.579,000News CoverageRVMDRevolution Medicines4.5764 of 5 stars$36.67-3.2%$67.58+84.3%-12.3%$7.05B$11.58M-9.17250LEGNLegend Biotech3.3981 of 5 stars$35.87+0.6%$72.60+102.4%-19.7%$6.55B$627.24M-60.802,609Analyst ForecastGRFSGrifols3.9722 of 5 stars$8.87-2.3%$10.30+16.1%+10.1%$6.24B$7.81B7.5823,822News CoverageTGTXTG Therapeutics3.7966 of 5 stars$35.98-2.0%$40.80+13.4%+73.4%$5.83B$329M149.92290News CoveragePositive NewsAnalyst UpgradeNUVLNuvalent3.3079 of 5 stars$77.93-3.2%$119.60+53.5%+3.8%$5.78BN/A-17.7540Insider Trade Related Companies and Tools Related Companies BBIO Competitors BPMC Competitors VRNA Competitors ROIV Competitors ELAN Competitors RVMD Competitors LEGN Competitors GRFS Competitors TGTX Competitors NUVL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
